Regeneron Pharmaceuticals (REGN) Resumen de Acciones
Regeneron Pharmaceuticals, Inc. descubre, inventa, desarrolla, fabrica y comercializa medicamentos para tratar diversas enfermedades en todo el mundo. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 6/6 |
| Crecimiento futuro | 1/6 |
| Rendimiento pasado | 1/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
REGN ha superado nuestros controles de riesgos.
REGN Community Fair Values
Create NarrativeSee what 163 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Regeneron Pharmaceuticals, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$654.27 |
| Máximo en las últimas 52 semanas | US$821.11 |
| Mínimo de 52 semanas | US$532.60 |
| Beta | 0.24 |
| Cambio en 1 mes | 2.96% |
| Variación en 3 meses | -14.25% |
| Cambio de 1 año | 19.53% |
| Variación en 3 años | -5.51% |
| Variación en 5 años | 12.73% |
| Variación desde la OPV | 2,997.14% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jun 24
REGN: Core Immunology Cash Flows Will Support Pipeline And Oncology Upside
Regeneron Pharmaceuticals' updated analyst fair value has shifted lower by about $42 to $833, as analysts factor in reduced expectations for the fianlimab program after recent Phase 3 trial disappointments, softer modeled revenue growth and margins, and a lower assumed future P/E multiple. Analyst Commentary Recent research on Regeneron Pharmaceuticals centers on the impact of fianlimab trial results, competitive pressures around key franchises, and how these factors feed into earnings forecasts and valuation multiples.
Actualización de narrativa • Jun 09
REGN: Future Re Rating Will Hinge On Reset Oncology Pipeline Optionality
Analysts have reduced their fair value estimate for Regeneron Pharmaceuticals to $1,000 from $1,030 after a series of lower Street price targets followed the company’s disappointing Phase 3 fianlimab and LAG-3 melanoma trial results. Analyst Commentary Street research following the fianlimab and LAG-3 melanoma trial update has been active, with most recent moves skewed toward lower fair value assumptions and, in some cases, rating downgrades.Recent updates
Actualización de narrativa • Jun 24
REGN: Core Immunology Cash Flows Will Support Pipeline And Oncology Upside
Regeneron Pharmaceuticals' updated analyst fair value has shifted lower by about $42 to $833, as analysts factor in reduced expectations for the fianlimab program after recent Phase 3 trial disappointments, softer modeled revenue growth and margins, and a lower assumed future P/E multiple. Analyst Commentary Recent research on Regeneron Pharmaceuticals centers on the impact of fianlimab trial results, competitive pressures around key franchises, and how these factors feed into earnings forecasts and valuation multiples.Actualización de narrativa • Jun 09
REGN: Future Re Rating Will Hinge On Reset Oncology Pipeline Optionality
Analysts have reduced their fair value estimate for Regeneron Pharmaceuticals to $1,000 from $1,030 after a series of lower Street price targets followed the company’s disappointing Phase 3 fianlimab and LAG-3 melanoma trial results. Analyst Commentary Street research following the fianlimab and LAG-3 melanoma trial update has been active, with most recent moves skewed toward lower fair value assumptions and, in some cases, rating downgrades.
Actualización de narrativa • May 26
REGN: Fair Outlook As LAG 3 Setback Reshapes Pipeline And Product Prospects
Analysts have trimmed their fair value estimate for Regeneron Pharmaceuticals to $641 from $730, reflecting lower assumed profit margins and a reduced future P/E multiple after the recent fianlimab LAG-3 trial setbacks and related cuts to price targets across the Street. Analyst Commentary Street research has turned more cautious on Regeneron following the failed Phase 3 LAG-3 melanoma trial for fianlimab, with a series of reduced price targets and several rating downgrades.Seeking Alpha • May 18
Regeneron: Time To Forget Fianlimab (Rating Upgrade)
Summary Regeneron faced a setback after fianlimab and Libtayo failed in a phase 3 trial in first-line metastatic melanoma. These results have negative read-through to other fianlimab-based trials in melanoma. I see Regeneron as a strong buy after the pullback, as fianlimab-based combinations were not critical for long-term value creation. Return to stronger growth, expanding and maturing pipeline, and a strong balance sheet position the company well for success. Key risks include further Eylea franchise weakness and potential new clinical disappointments. Read the full article on Seeking AlphaActualización de narrativa • May 03
REGN: Expanding Immunology And Gene Therapy Will Support Future Upside
Regeneron's analyst price target has been adjusted slightly higher to $875.31 from $873.78, as analysts factor in updated assumptions around revenue growth, profitability, and future P/E multiples following a mix of recent target hikes and trims across the Street. Analyst Commentary Recent Street research on Regeneron Pharmaceuticals shows a mix of optimism and caution, reflected in a series of price target raises and trims clustered over the past few months.Actualización de narrativa • Apr 19
REGN: Fair Outlook As Mixed Pipeline And Product Trends Shape Prospects
Regeneron Pharmaceuticals' updated analyst price target holds at $730, as analysts balance modest tweaks to growth, margins, and discount rate assumptions with recent Street research that broadly reiterates support for Dupixent, the broader pipeline, and capital return from the Sanofi repayment. Analyst Commentary Recent Street research around Regeneron points to a mixed but generally supportive tone, with several firms adjusting price targets and reiterating constructive views on Dupixent, the pipeline, and cash inflows from the Sanofi repayment.Actualización de narrativa • Apr 04
REGN: Future Share Re Rating Seen Building On Underappreciated Immunology Pipeline
Analysts have modestly lifted their fair value estimate for Regeneron Pharmaceuticals to $1,030.49. The new estimate is supported by updated models that incorporate Street research pointing to stronger Dupixent contribution, an undervalued pipeline, and slightly higher assumed revenue growth, profit margins, and future P/E levels.Actualización de narrativa • Mar 21
REGN: Expanding Immunology Franchise Will Support Future Upside Despite Concentration Risks
Analysts have raised their price targets on Regeneron, with the modelled fair value estimate moving from about $821.12 to $873.78 as they factor in stronger contributions from Dupixent, a higher revenue growth outlook, firmer profit margins, and a slightly lower assumed future P/E multiple. Analyst Commentary Bullish and cautious voices around Regeneron are both active, with recent research focused on how much of Dupixent's profit stream and the broader pipeline are already reflected in the share price.Actualización de narrativa • Mar 07
REGN: Fair Outlook As Pipeline Optionality Offsets Product And Competition Risks
Analysts have nudged their average price target for Regeneron higher into the low $900s, reflecting views that Dupixent profitability, indication expansion, and an undervalued pipeline, including Lynozyfic, are not fully reflected in the current share price. Analyst Commentary Recent research on Regeneron centers on whether the market is giving full credit to Dupixent and the broader pipeline versus risks tied to older products and future competition.Actualización de narrativa • Feb 21
REGN: Fair Outlook As Future Pipeline And Spending Risks Remain
Analysts have raised their fair value estimate for Regeneron to $730 from $627, reflecting updated models that incorporate higher projected revenue growth, slightly stronger profit margins, and a modestly richer future P/E multiple, in line with a series of recent price target increases across the Street. Analyst Commentary Recent Street research on Regeneron has tilted positive, with a series of higher price targets from firms including Goldman Sachs, Citi, JPMorgan and others.Actualización de narrativa • Feb 06
REGN: 2026 Oncology Milestones Are Expected To Drive Share Re Rating
Analysts have nudged our Regeneron Pharmaceuticals fair value estimate higher to US$1,009.20 from US$995.67, reflecting updated price targets that lean on stronger modeled revenue growth assumptions, a modestly adjusted discount rate, slightly lower profit margin expectations, and a marginally lower future P/E multiple. Analyst Commentary Recent Street research around Regeneron has leaned firmly positive, with a cluster of bullish analysts lifting price targets across a tight time window.Actualización de narrativa • Jan 23
REGN: Pipeline Catalysts In 2026 Are Expected To Drive Re Rating
Analysts have lifted their fair value estimate for Regeneron Pharmaceuticals from US$890.00 to about US$995.67, reflecting higher modeled revenue growth and profit margins, alongside a slightly lower future P/E assumption and an updated discount rate. Analyst Commentary Recent research on Regeneron Pharmaceuticals has tilted clearly positive, with a series of higher price targets and supportive coverage pointing to confidence in the company’s execution, portfolio strength, and pipeline potential.Actualización de narrativa • Jan 09
REGN: Core Franchises And Pipeline Will Support Balanced Upside And Concentration Risks
Analysts have raised their fair value estimate for Regeneron Pharmaceuticals from about $781 to roughly $821. This reflects updated price targets that reference a slightly lower discount rate, modestly adjusted revenue growth assumptions, a small uptick in expected profit margins, and a higher future P/E multiple supported by recent bullish research calls from several major firms.Actualización de narrativa • Dec 25
REGN: Future Pipeline And Spending Risks Likely To Pressure Shares
Analysts have lifted their fair value estimate for Regeneron Pharmaceuticals to $627 from $543, citing faster expected revenue growth, improved long term profit margins, and a still compelling valuation multiple despite a modestly higher discount rate. Analyst Commentary Recent Street research on Regeneron highlights a generally positive stance on the company, with most firms reiterating or initiating Buy or Outperform ratings and lifting price targets following a strong third quarter.Actualización de narrativa • Dec 11
REGN: Core Franchises And Pipeline Will Support Measured Upside Amid Ongoing Risks
Regeneron Pharmaceuticals fair value estimate has been nudged higher to approximately $781 per share from about $768, as analysts factor in stronger medium term revenue growth, expanding profit margins, and a durable innovation led pipeline that supports higher long term earnings power despite modestly lower future multiple assumptions. Analyst Commentary Recent Street research on Regeneron reflects a generally constructive stance, with most firms reiterating or initiating positive ratings while modestly recalibrating price targets around execution risks and spending needs.Actualización de narrativa • Nov 27
REGN: Core Franchises And Upcoming Catalysts Will Drive Measured Upside Amid Risks
Regeneron Pharmaceuticals' analyst price target has been increased from approximately $753 to $768, as analysts highlight the company's resilient commercial base, innovative pipeline, and anticipated near-term contributions from core franchises and upcoming catalysts. Analyst Commentary Recent coverage of Regeneron Pharmaceuticals by Wall Street analysts reflects a broad consensus of confidence in the company's long-term growth drivers, while also acknowledging areas of risk that could impact future valuation and execution.Artículo de análisis • Nov 19
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
The Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) share price has done very well over the last month, posting an...Actualización de narrativa • Nov 12
REGN: Positive Trial Results And Approval Will Drive Continued Momentum
Regeneron's analyst price target has increased from approximately $735.72 to $753.17, as analysts cite better-than-expected quarterly results and continued strength across key product lines as drivers for the higher valuation. Analyst Commentary Bullish Takeaways Bullish analysts highlight the robust Q3 results, which surpassed expectations for both revenue and earnings.Artículo de análisis • Nov 09
Regeneron Pharmaceuticals' (NASDAQ:REGN) Anemic Earnings Might Be Worse Than You Think
Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) stock showed strength, with investors undeterred by its weak earnings...Actualización de narrativa • Oct 28
Pipeline Strength And Recent Developments Will Drive Premium Potential Ahead
Regeneron's analyst price target increased from $722.20 to $735.72, reflecting improved earnings results and confidence in the company's drug pipeline, according to recent analyst commentary. Analyst Commentary Following Regeneron Pharmaceuticals' recent earnings results and updates across its drug pipeline, analysts have issued a series of updated price targets and recommendations.Actualización de narrativa • Sep 18
Broad Pipeline And Global Access Will Build Future Success
Regeneron Pharmaceuticals’ price target was raised to $722.20 as analysts cited continued outperformance and growth potential for Dupixent and Eylea, strong late-stage trial results in myasthenia gravis, and reinforced market leadership following competitor setbacks. Analyst Commentary Bullish analysts highlighted ongoing strength and growth potential for Dupixent and Eylea, with market share remaining dominant and robust prospects for Eylea HD.Rentabilidad de los accionistas
| REGN | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 3.4% | 4.1% | 1.6% |
| 1Y | 19.5% | 41.1% | 18.6% |
Rentabilidad vs. Industria: Los resultados de REGN fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 41.1% el año pasado.
Rentabilidad vs. Mercado: REGN igualó el mercado US, que obtuvo un rendimiento del 18.6% el año pasado.
Volatilidad de los precios
| REGN volatility | |
|---|---|
| REGN Average Weekly Movement | 4.8% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: REGN no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de REGN (5%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1988 | 15,343 | Leonard Schleifer | www.regeneron.com |
Regeneron Pharmaceuticals, Inc. descubre, inventa, desarrolla, fabrica y comercializa medicamentos para tratar diversas enfermedades en todo el mundo. La empresa desarrolla productos candidatos para el tratamiento de enfermedades oculares, alérgicas e inflamatorias, cardiovasculares, metabólicas, neurológicas, infecciosas y raras, así como del cáncer y de trastornos hematológicos. También ofrece inyecciones de EYLEA para la degeneración macular húmeda relacionada con la edad y el edema macular diabético; la neovascularización coroidea miópica; la retinopatía diabética; el glaucoma neovascular; la retinopatía del prematuro; la inyección de Dupixent para tratar la dermatitis atópica y el asma; la inyección de Libtayo para el carcinoma cutáneo de células escamosas metastásico o localmente avanzado; la inyección de Praluent para tratar la hipercolesterolemia familiar heterocigótica (HoFH); y la solución de Kevzara para la artritis reumatoide.
Resumen de fundamentos de Regeneron Pharmaceuticals, Inc.
| Estadísticas fundamentales de REGN | |
|---|---|
| Capitalización bursátil | US$66.56b |
| Beneficios(TTM) | US$4.42b |
| Ingresos (TTM) | US$14.92b |
15.0x
Ratio precio-beneficio (PE)4.5x
Ratio precio-ventas (PS)¿Está REGN sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de REGN | |
|---|---|
| Ingresos | US$14.92b |
| Coste de los ingresos | US$8.37b |
| Beneficio bruto | US$6.55b |
| Otros gastos | US$2.12b |
| Beneficios | US$4.42b |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
Jul 30, 2026
| Beneficios por acción (BPA) | 43.48 |
| Margen bruto | 43.89% |
| Margen de beneficio neto | 29.65% |
| Ratio deuda/patrimonio | 6.3% |
¿Cómo se ha desempeñado REGN a largo plazo?
Ver rendimiento histórico y comparativaDividendos
0.6%
Rentabilidad actual por dividendo8%
Ratio de pagosAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/05 02:50 |
| Precio de las acciones al final del día | 2026/07/02 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Regeneron Pharmaceuticals, Inc. está cubierta por 53 analistas. 27 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Brian Skorney | Baird |
| Eliana Merle | Barclays |